AU6268196A - Gene therapy for myocardial ischemia - Google Patents

Gene therapy for myocardial ischemia

Info

Publication number
AU6268196A
AU6268196A AU62681/96A AU6268196A AU6268196A AU 6268196 A AU6268196 A AU 6268196A AU 62681/96 A AU62681/96 A AU 62681/96A AU 6268196 A AU6268196 A AU 6268196A AU 6268196 A AU6268196 A AU 6268196A
Authority
AU
Australia
Prior art keywords
gene therapy
myocardial ischemia
ischemia
myocardial
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU62681/96A
Other languages
English (en)
Inventor
Wolfgang H. Dillmann
Frank J Giordano
Ruben Mestril
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of AU6268196A publication Critical patent/AU6268196A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU62681/96A 1995-06-07 1996-06-07 Gene therapy for myocardial ischemia Abandoned AU6268196A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US481122 1983-04-01
US48112295A 1995-06-07 1995-06-07
PCT/US1996/009858 WO1996040195A1 (fr) 1995-06-07 1996-06-07 Therapie genique pour ischemie myocardique

Publications (1)

Publication Number Publication Date
AU6268196A true AU6268196A (en) 1996-12-30

Family

ID=23910695

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62681/96A Abandoned AU6268196A (en) 1995-06-07 1996-06-07 Gene therapy for myocardial ischemia

Country Status (4)

Country Link
EP (1) EP0831874A4 (fr)
AU (1) AU6268196A (fr)
CA (1) CA2221710A1 (fr)
WO (1) WO1996040195A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998386A (en) * 1997-09-19 1999-12-07 Feldman; Arthur M. Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue
CA2715765A1 (fr) 2008-02-19 2009-08-27 Celladon Corporation Compositions pour un captage ameliore de vecteurs viraux dans le myocarde

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5346812A (en) * 1989-09-07 1994-09-13 The University Of Miami Teratogen assay
US5071962A (en) * 1990-05-31 1991-12-10 The United State Of America As Represented By The Department Of Health And Human Services Nucleotide, deduced amino acid sequence, isolation and purification of heat-shock chlamydial proteins
US5443836A (en) * 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage

Also Published As

Publication number Publication date
EP0831874A1 (fr) 1998-04-01
EP0831874A4 (fr) 2002-03-06
CA2221710A1 (fr) 1996-12-19
WO1996040195A1 (fr) 1996-12-19

Similar Documents

Publication Publication Date Title
AU4787697A (en) Therapeutic gene
AU5671696A (en) Scytalidium catalase gene
AU7489896A (en) Feed enzyme preparations
AU699706C (en) Improved vectors for gene therapy
AU7019494A (en) Genetic therapy for cardiovascular disease
AU8116494A (en) Gene signature
AU6011496A (en) Improved pharmaceutical compositions for gene therapy
AU5441896A (en) Cooperative oligonucleotides
AU3737297A (en) Bacteriophage-mediated gene therapy
AUPN245295A0 (en) Assay for genetic abnormalities
AU5590394A (en) Transglutaminase gene
AU4401297A (en) Improved retroviral vectors for gene therapy
AU6659998A (en) Tazarotene-induced gene 3 (tig3)
AU6254799A (en) Anti-ige gene therapy
AU4941096A (en) Self-deleting vectors for gene therapy
AU6960396A (en) Batten disease gene
AU2611695A (en) Sailboatsystem for controlled gibing
AU6268196A (en) Gene therapy for myocardial ischemia
AU3036197A (en) Adenovirus vectors for gene therapy
AUPP058797A0 (en) Novel gene
AU1045199A (en) Cancer gene
AUPN614495A0 (en) Progestin-regulated gene
AU7266996A (en) Progestin-regulated gene
AU4955096A (en) Novel gene recombinant
AU2002300391A1 (en) Gene transfer-mediated angiogenesis therapy